Towards New Therapies for Parkinson's Disease / / edited by David I Finkelstein.

Parkinson's disease (PD) is characterised clinically by various non-motor and progressive motor symptoms, pathologically by loss of dopamine producing cells and intraneuronal cytoplasmic inclusions composed primarily of ?-synuclein. By the time a patient first presents with symptoms of Parkinso...

Full description

Saved in:
Bibliographic Details
TeilnehmendeR:
Place / Publishing House:Croatia : : IntechOpen,, 2011.
Year of Publication:2011
Language:English
Physical Description:1 online resource (410 pages)
Tags: Add Tag
No Tags, Be the first to tag this record!
LEADER 00885nam a2200277 i 4500
001 993547431304498
005 20221010201200.0
006 m o d
007 cr |||||||||||
008 221010s2011 ci o 000 0 eng d
020 |a 953-51-6545-3 
035 |a (CKB)3230000000077137 
035 |a (NjHacI)993230000000077137 
035 |a (oapen)https://directory.doabooks.org/handle/20.500.12854/65253 
035 |a (EXLCZ)993230000000077137 
040 |a NjHacI  |b eng  |e rda  |c NjHacl 
041 0 |a eng 
050 4 |a R742.5  |b .T693 2011 
082 0 4 |a 150  |2 23 
100 1 |a Finkelstein, David I.  |4 edt 
245 0 0 |a Towards New Therapies for Parkinson's Disease /  |c edited by David I Finkelstein. 
260 |b IntechOpen  |c 2011 
264 1 |a Croatia :  |b IntechOpen,  |c 2011. 
300 |a 1 online resource (410 pages) 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
588 |a Description based on publisher supplied metadata and other sources. 
520 |a Parkinson's disease (PD) is characterised clinically by various non-motor and progressive motor symptoms, pathologically by loss of dopamine producing cells and intraneuronal cytoplasmic inclusions composed primarily of ?-synuclein. By the time a patient first presents with symptoms of Parkinson's disease at the clinic, a significant proportion of the cells in the substantia nigra have already been destroyed. This degeneration progresses despite the current therapies until the cell loss is so great that the quality of normal life is compromised. The dopamine precursor levodopa is the most valuable drug currently available for the treatment of PD. However for most PD patients, the optimal clinical benefit from levodopa decreases around five to six years of treatment. The aim of the chapters of this book is to work towards an understanding in the mechanisms of degeneration and to develop disease modifying therapies. 
546 |a English 
650 0 |a Psychology. 
653 |a Physiological & neuro-psychology, biopsychology 
776 |z 953-307-463-9 
700 1 |a Finkelstein, David I,  |e editor. 
906 |a BOOK 
ADM |b 2023-02-22 19:44:36 Europe/Vienna  |f system  |c marc21  |a 2012-12-09 08:17:33 Europe/Vienna  |g false 
AVE |i DOAB Directory of Open Access Books  |P DOAB Directory of Open Access Books  |x https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&portfolio_pid=5338571940004498&Force_direct=true  |Z 5338571940004498  |b Available  |8 5338571940004498